BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 26922744)

  • 21. Role of the phosphatidylinositol 3-kinase/Akt and mTOR/P70S6-kinase pathways in the proliferation and apoptosis in multiple myeloma.
    Pene F; Claessens YE; Muller O; Viguié F; Mayeux P; Dreyfus F; Lacombe C; Bouscary D
    Oncogene; 2002 Sep; 21(43):6587-97. PubMed ID: 12242656
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacodynamic Models of Differential Bortezomib Signaling Across Several Cell Lines of Multiple Myeloma.
    Ramakrishnan V; Mager DE
    CPT Pharmacometrics Syst Pharmacol; 2019 Mar; 8(3):146-157. PubMed ID: 30516019
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Silybin suppresses cell proliferation and induces apoptosis of multiple myeloma cells via the PI3K/Akt/mTOR signaling pathway.
    Feng N; Luo J; Guo X
    Mol Med Rep; 2016 Apr; 13(4):3243-8. PubMed ID: 26936429
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Apocynin inhibits Toll-like receptor-4-mediated activation of NF-κB by suppressing the Akt and mTOR pathways.
    Nam YJ; Kim A; Sohn DS; Lee CS
    Naunyn Schmiedebergs Arch Pharmacol; 2016 Dec; 389(12):1267-1277. PubMed ID: 27590200
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Knockdown of DEPTOR inhibits cell proliferation and increases chemosensitivity to melphalan in human multiple myeloma RPMI-8226 cells via inhibiting PI3K/AKT activity.
    Zhang HR; Chen JM; Zeng ZY; Que WZ
    J Int Med Res; 2013 Jun; 41(3):584-95. PubMed ID: 23613505
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Human anti-CD40 antagonist antibody triggers significant antitumor activity against human multiple myeloma.
    Tai YT; Li X; Tong X; Santos D; Otsuki T; Catley L; Tournilhac O; Podar K; Hideshima T; Schlossman R; Richardson P; Munshi NC; Luqman M; Anderson KC
    Cancer Res; 2005 Jul; 65(13):5898-906. PubMed ID: 15994968
    [TBL] [Abstract][Full Text] [Related]  

  • 27. MLN120B, a novel IkappaB kinase beta inhibitor, blocks multiple myeloma cell growth in vitro and in vivo.
    Hideshima T; Neri P; Tassone P; Yasui H; Ishitsuka K; Raje N; Chauhan D; Podar K; Mitsiades C; Dang L; Munshi N; Richardson P; Schenkein D; Anderson KC
    Clin Cancer Res; 2006 Oct; 12(19):5887-94. PubMed ID: 17020997
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prevention of cytokine-induced apoptosis by insulin-like growth factor-I is independent of cell adhesion molecules in HT29-D4 colon carcinoma cells-evidence for a NF-kappaB-dependent survival mechanism.
    Garrouste F; Remacle-Bonnet M; Fauriat C; Marvaldi J; Luis J; Pommier G
    Cell Death Differ; 2002 Jul; 9(7):768-79. PubMed ID: 12058282
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Simultaneous targeting of PI3K and mTOR with NVP-BGT226 is highly effective in multiple myeloma.
    Baumann P; Schneider L; Mandl-Weber S; Oduncu F; Schmidmaier R
    Anticancer Drugs; 2012 Jan; 23(1):131-8. PubMed ID: 21959532
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A novel NF-kappaB inhibitor DHMEQ selectively targets constitutive NF-kappaB activity and induces apoptosis of multiple myeloma cells in vitro and in vivo.
    Watanabe M; Dewan MZ; Okamura T; Sasaki M; Itoh K; Higashihara M; Mizoguchi H; Honda M; Sata T; Watanabe T; Yamamoto N; Umezawa K; Horie R
    Int J Cancer; 2005 Mar; 114(1):32-8. PubMed ID: 15523684
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Tetraspanins affect myeloma cell fate via Akt signaling and FoxO activation.
    Lishner M; Zismanov V; Tohami T; Tartakover-Matalon S; Elis A; Drucker L
    Cell Signal; 2008 Dec; 20(12):2309-16. PubMed ID: 18804164
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The phosphatidylinositol 3-kinase/AKT kinase pathway in multiple myeloma plasma cells: roles in cytokine-dependent survival and proliferative responses.
    Tu Y; Gardner A; Lichtenstein A
    Cancer Res; 2000 Dec; 60(23):6763-70. PubMed ID: 11118064
    [TBL] [Abstract][Full Text] [Related]  

  • 33. NF-κB dysregulation in multiple myeloma.
    Matthews GM; de Matos Simoes R; Dhimolea E; Sheffer M; Gandolfi S; Dashevsky O; Sorrell JD; Mitsiades CS
    Semin Cancer Biol; 2016 Aug; 39():68-76. PubMed ID: 27544796
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Canonical nuclear factor kappaB pathway inhibition blocks myeloma cell growth and induces apoptosis in strong synergy with TRAIL.
    Romagnoli M; Desplanques G; Maïga S; Legouill S; Dreano M; Bataille R; Barillé-Nion S
    Clin Cancer Res; 2007 Oct; 13(20):6010-8. PubMed ID: 17947462
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Expression and function of toll-like receptors in multiple myeloma patients: toll-like receptor ligands promote multiple myeloma cell growth and survival via activation of nuclear factor-kappaB.
    Xu Y; Zhao Y; Huang H; Chen G; Wu X; Wang Y; Chang W; Zhu Z; Feng Y; Wu D
    Br J Haematol; 2010 Sep; 150(5):543-53. PubMed ID: 20629663
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Brefeldin A reduces tumor necrosis factor-α-stimulated production of inflammatory mediators by suppressing the Akt, mTOR, and NF-κB pathways in human keratinocytes.
    Nam YJ; Lee CS
    Naunyn Schmiedebergs Arch Pharmacol; 2016 Sep; 389(9):951-60. PubMed ID: 27198515
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Mechanisms of cell death and survival in multiple myeloma (MM): Therapeutic implications.
    Chauhan D; Anderson KC
    Apoptosis; 2003 Aug; 8(4):337-43. PubMed ID: 12815276
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Interference with nuclear factor kappa B and c-Jun NH2-terminal kinase signaling by TRAF6C small interfering RNA inhibits myeloma cell proliferation and enhances apoptosis.
    Chen H; Li M; Campbell RA; Burkhardt K; Zhu D; Li SG; Lee HJ; Wang C; Zeng Z; Gordon MS; Bonavida B; Berenson JR
    Oncogene; 2006 Oct; 25(49):6520-7. PubMed ID: 16702955
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Knockdown of DEPTOR induces apoptosis, increases chemosensitivity to doxorubicin and suppresses autophagy in RPMI-8226 human multiple myeloma cells in vitro.
    Zhang H; Chen J; Zeng Z; Que W; Zhou L
    Int J Mol Med; 2013 May; 31(5):1127-34. PubMed ID: 23503641
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Therapeutic enhancement of ER stress by insulin-like growth factor I sensitizes myeloma cells to proteasomal inhibitors.
    Tagoug I; Jordheim LP; Herveau S; Matera EL; Huber AL; Chettab K; Manié S; Dumontet C
    Clin Cancer Res; 2013 Jul; 19(13):3556-66. PubMed ID: 23674497
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.